Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:53:49 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:BYSI from 2023-05-04 to 2024-05-03 - 18 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-03 07:00U:BYSINews ReleaseBeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
2024-04-29 17:30U:BYSINews ReleaseBeyondSpring Files 2023 Annual Report on Form 20-F
2024-04-29 17:30U:BYSINews ReleaseBeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
2024-03-25 07:00U:BYSINews ReleaseBeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
2024-02-26 08:00U:BYSINews ReleaseBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
2024-01-10 15:00U:BYSINews ReleaseBeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
2023-12-18 16:30U:BYSINews ReleaseBeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
2023-11-07 07:00U:BYSINews ReleaseBeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor
2023-10-31 08:00U:BYSINews ReleaseBeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin ¢ € ™s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
2023-10-30 08:00U:BYSINews ReleaseBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-10-26 08:30U:BYSINews ReleaseSEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at ¢ € œTargeted Protein Degradation Think Tank ¢ €  Symposium
2023-10-23 07:45U:BYSINews ReleaseSEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
2023-10-04 15:55U:BYSINews ReleaseBeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
2023-09-27 10:00U:BYSINews ReleaseBeyondSpring and Leading Cancer Center to Present Poster at SITC ¢ € ™s 38th Annual Meeting
2023-09-07 08:00U:BYSINews ReleaseBeyondSpring to Participate in the R.W. Baird ¢ € ™s 2023 Global Healthcare Conference
2023-06-20 08:00U:BYSINews ReleaseSEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
2023-06-07 08:00U:BYSINews ReleaseBeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin ¢ € ™s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
2023-05-18 08:30U:BYSINews ReleaseBeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting